
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
NEW YORK–(BUSINESS WIRE) November 23, 2020 — Pfizer Inc. (NYSE: PFE) today announced that the